Sign in Subscribe
By staff in News —

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - Stocktwits

Roth Capital said the FDA’s acceptance shows strong confidence in Cingulate’s ADHD drug, adding that its early PDUFA date and clean regulatory path make it a good investment.

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating. 

Cingulate Inc.’s stock snapped a two-day losing streak, rising 2.5% to $4.15 on Tuesday, and added another 1.6% in after-hours trading.

The firm said the FDA’s acceptance of Cingulate’s application for its ADHD drug CTx-1301 signals confidence in the treatment’s safety and effectiveness for both children and adults.

Roth analysts said the absence of an Advisory Committee review, an earlier-than-expected PDUFA date of May 31, 2026, and a potentially broad label across ADHD patients all strengthen the investment case for Cingulate. They also highlighted the strong approval track record of ADHD stimulants as supportive of the drug’s prospects.

The FDA’s acceptance marks a major step forward for CTx-1301, which uses Cingulate’s proprietary Precision Timed Release technology to deliver once-daily, all-day symptom control. The company said Phase 3 data showed rapid onset and sustained efficacy with no serious safety issues reported.

The company called the FDA acceptance a “defining milestone”, positioning Cingulate to transition from a development-stage to a commercial-stage company in 2026, pending approval. The firm said commercial preparations are already underway through partnerships with Bend Bio Sciences and Indegene to ensure manufacturing scale-up and market readiness.

On Stocktwits, retail sentiment for Cingulate was ‘bullish’ amid an 820% surge in 24-hour message volume.

One bullish user highlighted the advantages of Cingulate’s regulatory route, noting it follows a faster and less expensive path typically used for drugs that build on existing approvals with new delivery methods. They noted the company’s silence on social media could hint at buyout interest and said they would only part with their shares for $27.

Another bullish user noted that, with the NDA now accepted, the real question for investors was the risk they were taking by not owning the stock at this stage. They added that long-term holders were feeling more confident than ever about the company’s direction.

Cingulate’s stock has declined 16% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share·

Add us on

Subscribe to Chart Art

Get the daily crypto email you’ll actually love to read. It's value-packed, data-driven, and seasoned with wit.

Read about our editorial guidelines and ethics policy

Overview

Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent condition affecting many adults in the UK. Understanding the ADHD symptoms adults UK experience is crucial for effective management and treatment. This article explores the latest developments regarding Cingulate's ADHD drug, CTx-1301, which may soon offer new treatment options for those living with ADHD. This topic is essential as it highlights promising advancements in ADHD medication and underscores the importance of staying informed about ADHD treatment options.

Recent insights indicate that Cingulate's progress through the FDA approval process could signal a significant shift in ADHD management. The initial findings suggest that this medication could provide symptom control with a once-daily dosage, making it an attractive option for adults seeking effective solutions. The implications of these developments are profound, potentially enhancing the quality of life for many.

Key Details

Cingulate's stock recently recovered from a two-day decline after Roth Capital Partners raised its price target, showcasing growing confidence in the company's ADHD drug, CTx-1301. The FDA's acceptance of Cingulate’s application is a strong indicator of the treatment's potential safety and effectiveness for both children and adults. This acceptance is crucial as it comes without an Advisory Committee review and features an early PDUFA date of May 31, 2026, suggesting a streamlined pathway to market.

Roth analysts emphasised that the absence of prior committee scrutiny and the promising Phase 3 data, which indicated rapid onset and sustained efficacy without serious safety issues, strengthen the case for Cingulate's investment potential. This aligns with the historical success of stimulant medications in treating ADHD, reinforcing optimism around CTx-1301. The company’s proprietary Precision Timed Release technology is designed to deliver all-day symptom control, which could greatly benefit adults struggling with ADHD management strategies.

As Cingulate prepares for potential market entry in 2026, they have initiated commercial preparations, collaborating with partners for manufacturing scale-up. This proactive approach positions the company well as it transitions from a developmental to a commercial stage. Retail sentiment among investors has been notably bullish, especially on platforms like Stocktwits, where discussions have surged significantly, indicating a heightened interest in Cingulate's future prospects.

Overall, the developments surrounding Cingulate's ADHD drug not only reflect the evolving landscape of ADHD medication UK but also offer hope for improved treatment options for those managing this condition. This is particularly relevant for adults in the UK who face unique challenges in accessing effective ADHD support.

Practical Takeaways

  • Discuss with your GP about the latest ADHD treatment options, including emerging medications like CTx-1301.
  • Stay informed about the FDA approval process for ADHD medications to better understand available treatments.
  • Consider joining online forums or communities to share experiences and gain insights from others living with ADHD.
  • Explore ADHD-friendly workplace strategies to enhance productivity and manage symptoms effectively.
  • Track symptoms and response to any new medication to discuss with your healthcare provider during follow-up appointments.
  • Research natural remedies that work for managing ADHD symptoms if you prefer a non-medication approach.
  • Utilise resources provided by organisations focused on adult ADHD support UK, such as helplines or support groups.

Bottom Line

The most crucial takeaway from this article is that significant advancements in ADHD treatment options, particularly Cingulate's CTx-1301, are on the horizon. Adults with ADHD in the UK will benefit from staying informed about these developments, as they may enhance management strategies and overall well-being. However, it is essential to remain cautious and consult with healthcare professionals regarding how to manage ADHD without medication or any new treatment options.

📰 Source: Read the full article

Subscribe to ADHD Compass

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe